September 23, 2008
BioMimetic Therapeutics Announces No Changes Requested by Independent Data Monitoring Committee to Pivotal Trial … (Centre Daily Times)
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today results from the independent Data Monitoring Committee (DMC) that is overseeing the Company’s ongoing U.S. pivotal trial evaluating Augment Bone Graft for the treatment of foot and ankle fusions. Based on the DMC’s review of all available safety data from the first 254 patients and a futility analysis on data from the first 79 patients … Full story…
Filed by Body Scans at 9:30 pm under Scan Articles